£0.00
0
0
Subtotal: £0.00

No products in the basket.

Research priorities and questions

The NIHR has rolling funding programmes linked to JLA PSP priorities and NICE research questions. Other funders may also be persuaded if you are answering a question identified through a robust process.

Top ten epilepsy research priorities

The top ten priorities for research into epilepsy were established by the UK epilepsy community, including people living with and affected by epilepsy, healthcare professionals and patient groups though a James Lind Alliance Priority Setting Partnership.1,2 

  1. What are the causes and contributing factors of epilepsy-related deaths, including Sudden Unexpected Death in Epilepsy (SUDEP), and how can these deaths be prevented?
  2. What underlying mechanisms cause epilepsy in children and in adults?
  3. What impact do epilepsy, seizures and anti-seizure medication (ASMs) have on brain health – including cognition, memory, learning, behaviour and mental health?
  4. How does epilepsy and epilepsy treatment impact neurodevelopment, and can this be managed or prevented?
  5. How can targeted, personalised medicine, such as gene therapy, be used to treat and/or prevent epilepsy?
  6. How can tools, devices and biological markers be used to accurately predict and prevent seizures and the onset of epilepsy?
  7. How do hormonal changes in women throughout the lifespan (puberty, pregnancy, menopause) impact epilepsy, and how can this impact be addressed?
  8. How can quality of life be improved for people with epilepsy, their families and carers, including those bereaved by epilepsy?
  9. What causes drug-resistant (refractory) epilepsy, and how can it be best treated?
  10. How can big data analysis, through artificial intelligence (Al) and machine learning, aid the diagnosis and management of epilepsy?

See the priorities ranked 11–25


NICE research questions

Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy syndromes with onset in childhood, for example, myoclonic-astatic epilepsy and Dravet syndrome? Go to NICE

Risk prediction tool for all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death in epilepsy (SUDEP) in people with epilepsy or those who have had a single seizure, and an external validation of a risk prediction tool to detect the probability of epilepsy-related death. Go to NICE

Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated? Go to NICE

Psychological treatments: What is the cost-effectiveness of providing tailored psychological treatments for people with epilepsy? Go to NICE

Antibody testing: What immunomodulation strategies are effective in people with defined autoimmune epilepsy syndromes? Go to NICE

Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy? Go to NICE

Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)? Go to NICE

Ketogenic diets: What is the short-term and long-term clinical and cost effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance and tolerability of ketogenic diets? Go to NICE

Monitoring antiseizure medications in women and girls: What is the clinical and cost effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy? Go to NICE

Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy?

  • Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin and zonisamide.
  • Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide. Go to NICE

CBD: What is the clinical and cost effectiveness of CBD in epileptic disorders in children, young people and adults? Go to NICE

Does the addition of THC to CBD have an effect on seizure frequency, brain structure and neuropsychological performance when compared with both CBD alone and placebo in epileptic disorders in children, young people and adults? Go to NICE

AEDs and pregnancy: What is the malformation rate and longer term neurodevelopmental outcome of children born to mothers who have taken AEDs during pregnancy? Go to NICE

Antiseizure medication for repeated or cluster seizures: What antiseizure medications (monotherapy or add-on) are effective in the treatment of repeated or cluster seizures? Go to NICE

Risk prediction tool for second seizure: Development of a risk prediction tool for second seizures in people with a single seizure, and an external validation of a risk prediction tool to detect the probability of a second seizure in people with a single seizure at baseline. Go to NICE

Infantile spasms: Does treatment response relate to cause in infantile spasms? Does early treatment success in seizure control and resolution of the hypsarrhythmic EEG influence the long-term developmental and cognitive outcomes more than the underlying cause of the spasms? Go to NICE

Treatment of convulsive status epilepticus (that is, not just refractory): What is the most effective and safest AED to treat:

  • established (usually lasting longer than 30 minutes) convulsive status epilepticus
  • refractory convulsive status epilepticus? Go to NICE


References

  1. Norton AC, Twohig-Bennett C, Smeaton M et al. Top Ten epilepsy research priorities: A UK priority setting partnership. Seizure 2025;125:152-161. doi:10.1016/j.seizure.2024.12.008.
  2. Norton AC, Smeaton M, Twohig-Bennett C, Thomas RH. What the Top Ten epilepsy research priorities mean for the UK research ecosystem. EBioMedicine 2024;100:104919. doi:10.1016/j.ebiom.2023.104919.
×